Dechra Pharmaceuticals PLC — Director's Dealing 2023

Oct 18, 2023

National Storage Mechanism | Additional information

RNS Number : 5731Q

Dechra Pharmaceuticals PLC

18 October 2023

18 October 2023

Dechra Pharmaceuticals PLC

(the Company)

LEI: 213800J4UVB5OWG8VX82

Notification and public disclosure of transactions by persons discharging managerial responsibilities (PDMRs)

The Company announces that on 18 October 2023 the following Directors were granted awards over Ordinary Shares of 1 pence each in the Company under the Dechra 2021 Deferred Bonus Plan:

Name of individual	Director	Type of award	Number of shares subject to award
Ian Page	Director	DBP Award - nil cost option	1,080
Paul Sandland	Director	DBP Award - nil cost option	715
Tony Griffin	Director	DBP Award - conditional award	356

In accordance with the Directors' Remuneration Policy, 33% of the annual bonus earned in respect of the Company's 2023 financial year has been deferred into a share award for Ian Page and Paul Sandland and 20% deferred for Tony Griffin. The awards will vest at the end of a deferral period of two years.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the Market Abuse Regulation.

Notification of Dealing Form

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Ian Page

2.

Reason for the notification

a)

Position/status

Director

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB0009633180

b)

Nature of the transaction

Grant of award over Ordinary Shares under the Company's Deferred Bonus Plan  

c)

Price(s) and volumes(s)

Price	Volume
Nil cost award	1,080

d)

Aggregated information

-    Aggregate volume

-    Price

N/A

e)

Date of the transaction

18 October 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Paul Sandland

2.

Reason for the notification

a)

Position/status

Director

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB0009633180

b)

Nature of the transaction

Grant of award over Ordinary Shares under the Company's Deferred Bonus Plan 

c)

Price(s) and volumes(s)

Price	Volume
Nil cost award	715

d)

Aggregated information

-    Aggregate volume

-    Price

N/A

e)

Date of the transaction

18 October 2023

f)

Place of the transaction

Outside a trading venue

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tony Griffin

2.

Reason for the notification

a)

Position/status

Director

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

Identification code

Ordinary Shares of 1 pence each

ISIN: GB0009633180

b)

Nature of the transaction

Grant of award over Ordinary Shares under the Company's Deferred Bonus Plan 

c)

Price(s) and volumes(s)

Price	Volume
Nil cost award	356

d)

Aggregated information

-    Aggregate volume

-    Price

N/A

e)

Date of the transaction

18 October 2023

f)

Place of the transaction

Outside a trading venue

For further information, please contact:

Melanie Hall, Company Secretary                          

Telephone number: 01606 814730

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUBDGUGBDGXI